{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:41:20Z","timestamp":1792698080820,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Latrophilins (LPHNs), a group of the G-protein\u2013coupled receptor to which a spider venom latrotoxin (LTX) is known to bind, remain largely uncharacterized in neoplastic diseases. In the present study, we aimed to determine the role of LPHNs in the progression of prostate cancer. We assessed the actions of LPHNs, including LPHN1, LPHN2, and LPHN3, in human prostate cancer lines via their ligand (e.g., \u03b1-LTX, FLRT3) treatment or shRNA infection, as well as in surgical specimens. In androgen receptor (AR)-positive LNCaP\/C4-2\/22Rv1 cells, dihydrotestosterone considerably increased the expression levels of LPHNs, while chromatin immunoprecipitation assay revealed the binding of endogenous ARs, including AR-V7, to the promoter region of each LPHN. Treatment with \u03b1-LTX or FLRT3 resulted in induction in the cell viability and migration of both AR-positive and AR-negative lines. \u03b1-LTX and FLRT3 also enhanced the expression of Bcl-2 and phosphorylated forms of JAK2 and STAT3. Meanwhile, the knockdown of each LPHN showed opposite effects on all of those mediated by ligand treatment. Immunohistochemistry in radical prostatectomy specimens further showed the significantly elevated expression of each LPHN in prostate cancer, compared with adjacent normal-appearing prostate, which was associated with a significantly higher risk of postoperative biochemical recurrence in both univariate and multivariable settings. These findings indicate that LPHNs function as downstream effectors of ARs and promote the growth of androgen-sensitive, castration-resistant, or even AR-negative prostate cancer.<\/jats:p>","DOI":"10.3390\/ijms25137289","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:58:42Z","timestamp":1719925122000},"page":"7289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8620-0710","authenticated-orcid":false,"given":"Yuki","family":"Teramoto","sequence":"first","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Elahi Najafi","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhya","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-5049","authenticated-orcid":false,"given":"Takuro","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-7769","authenticated-orcid":false,"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"},{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bju.14237","article-title":"Guideline of guidelines: Primary monotherapies for localised or locally advanced prostate cancer","volume":"122","author":"Lancee","year":"2018","journal-title":"BJU Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: The European Association of Urology prostate cancer guidelines panel recommendations","volume":"6","author":"Briers","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kanayama, M., Lu, C., Luo, J., and Antonarakis, E.S. (2021). AR splicing variants and resistance to AR targeting agents. Cancers, 13.","DOI":"10.3390\/cancers13112563"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/14728222.2023.2293757","article-title":"Novel signatures of prostate cancer progression and therapeutic resistance","volume":"27","author":"Wang","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Daniels, V.A., Luo, J., Paller, C.J., and Kanayama, M. (2024). Therapeutic approaches to targeting androgen receptor splice variants. Cells, 13.","DOI":"10.3390\/cells13010104"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"23239","DOI":"10.1074\/jbc.271.38.23239","article-title":"Isolation and biochemical characterization of a Ca2+-independent \u03b1-latrotoxin-binding protein","volume":"271","author":"Davletov","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1006\/bbrc.1996.1598","article-title":"The calcium-independent receptor of \u03b1-latrotoxin is not a neurexin","volume":"227","author":"Krasnoperov","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1515\/bmc-2014-0032","article-title":"Latrophilins updated","volume":"5","author":"Boucard","year":"2014","journal-title":"BioMol. Concepts"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32715","DOI":"10.1074\/jbc.273.49.32715","article-title":"\u03b1-Latrotoxin receptor CIRL\/latrophilin 1 (CL1) defined an unusual family of ubiquitous G-protein-linked receptors: G-protein coupling not required for triggering exocytosis","volume":"273","author":"Sugita","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1074\/jbc.M113.504779","article-title":"Latrophilins function as heterophilic cell-adhesion molecules by binding to teneurins","volume":"289","author":"Boucard","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.neubiorev.2021.11.041","article-title":"Review of rodent models of attention Deficit hyperactivity disorder","volume":"132","author":"Regan","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biopsych.2012.05.027","article-title":"Fetal programming effects of testosterone on the reward system and behavioral approach tendencies in humans","volume":"72","author":"Lombardo","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.biopsych.2016.09.022","article-title":"Maternal polycystic ovary syndrome and risk for attention-deficit\/hyperactivity disorder in the offspring","volume":"82","author":"Kosidou","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"ref_16","first-page":"457","article-title":"A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer","volume":"13","author":"Crowley","year":"2021","journal-title":"Res. Rep. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nchembio.642","article-title":"Inactive-state preassembly of Gq-coupled receptors and Gq heterodimers","volume":"7","author":"Qin","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4143\/crt.2015.153","article-title":"Aberrant epigenetic modification of LPHN2 function as a potential cisplatin-specific biomarker for human gastrointestinal cancer","volume":"48","author":"Jeon","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4149\/gpb_2018008","article-title":"Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1","volume":"37","author":"Kocibalova","year":"2018","journal-title":"Gen. Physiol. Biophys."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yasinska, I.M., Sakhnevych, S.S., Pavlova, L., Teo Hansen Seln\u00f8, A., Teuscher Abeleira, A.M., Benlaouer, O., Gon\u00e7alves Silva, I., Mosimann, M., Varani, L., and Bardelli, M. (2019). The tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01594"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41374-021-00721-3","article-title":"Driver mutations in ADGRL3 are involved in the evolution of ependymoma","volume":"102","author":"Wang","year":"2022","journal-title":"Lab. Invest."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1158\/1535-7163.MCT-20-0050","article-title":"Androgen receptor signaling reduces the efficacy of bacillus Calmette-Gu\u00e9rin therapy for bladder cancer via modulating Rab27b-induced exocytosis","volume":"19","author":"Mizushima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Goto, T., Yasui, M., Teramoto, Y., Nagata, Y., Mizushima, T., and Miyamoto, H. (2024). Latrophilin-3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis. Mol. Carcinogen., in press.","DOI":"10.1002\/mc.23783"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.neuron.2012.01.018","article-title":"Postsynaptic FLRT proteins are endogenous ligands for the black widow spider venom receptor Latrophilin and regulate excitatory synapse development","volume":"73","author":"Savas","year":"2012","journal-title":"Neuron"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature09208","article-title":"Diverse somatic mutation patterns and pathway alterations in human cancers","volume":"466","author":"Kan","year":"2010","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Elahi Najafi, M.A., Yasui, M., Teramoto, Y., Tatenuma, T., Jiang, G., and Miyamoto, H. (2023). GABBR2 as a downstream effector of the androgen receptor induces cisplatin resistance in bladder cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813733"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/pros.21323","article-title":"Expression of semenogelins I and II and its prognostic significance in human prostate cancer","volume":"71","author":"Canacci","year":"2011","journal-title":"Prostate"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kawahara, T., Teramoto, Y., Li, Y., Ishiguro, H., Gordetsky, J., Yang, Z., and Miyamoto, H. (2020). Impact of vasectomy on the development and progression of prostate cancer. Cancers, 12.","DOI":"10.3390\/cancers12082295"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.humpath.2012.02.008","article-title":"Seminal plasma proteins in prostatic carcinoma: Increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy","volume":"43","author":"Izumi","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_31","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:17Z","timestamp":1760108957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":32,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25137289"],"URL":"https:\/\/doi.org\/10.3390\/ijms25137289","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}